The Molecular Genomics Core in the Duke Molecular Physiology Institute (DMPI) has added a 10xGenomics in situ sequencing platform called Xenium.
The new platform allows for single cell spatial resolution of gene expression and provides spatial context of targeted RNA profiles within tissues.
For cancer research, Xenium has the potential to define tumor state, location, and state of immune cells, and can determine if there are lymphoid structures present.
For other tissues, researchers can examine the effects of disease features, like plaques or lesions, and/or the impact of drug response in relevant tissue regions and cell times. Signatures identified can be paired with complementary technologies and traditional histopathology approaches to develop the future of standard of care diagnostic platforms.
Xenium is available for use to all Duke researchers through the Molecular Genomics Core. Interested users can contact Karen Abramson for more information.